文献速递糖尿病

司美格鲁肽启动对合并用药影响的间断时间序列研究

Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-26

基于丹麦全国登记数据,纳入 2022 年 12 月至 2024 年 12 月期间启动司美格鲁肽用于体重管理的 189 392 名成人,分析启动前 24 个月与启动后 12 个月内 10 类合并用药处方变化。结果显示抗哮喘药、外用糖皮质激素、抗银屑病药、镇痛药、抗抑郁药、外用抗真菌药及降压药等处方量低于预期,而抗焦虑药使用增加。

要点

  • 司美格鲁肽启动后多种肥胖相关合并症用药处方低于预期
  • 抗焦虑药使用在启动后增加,且两年时仍处于升高水平
  • 降糖药减少主要见于非胰岛素类药物,需注意阴性对照也有类似变化

核心结论

  • 司美格鲁肽用于体重管理启动后,多类肥胖相关合并症合并用药处方量低于基于启动前趋势的预期值,同时抗焦虑药使用增加
  • 其他治疗类别变化有限或仅为一过性,提示司美格鲁肽治疗可能影响整体用药模式

研究设计与样本

  • 丹麦全国登记数据的间断时间序列研究,纳入 2022 年 12 月至 2024 年 12 月启动司美格鲁肽用于体重管理的成人
  • 共 189 392 名使用者,其中 68% 为女性,中位年龄 50 岁
  • 分析启动前 24 个月和启动后 12 个月内 10 类药物的每月处方量,以率比(RR)比较观察值与基于启动前趋势的预期值

主要发现

  • 启动后 12 个月,抗哮喘药处方低于预期(RR:0.82,95%CI 0.79–0.86)
  • 外用糖皮质激素(RR:0.91,95%CI 0.87–0.96)、抗银屑病药(RR:0.91,95%CI 0.83–1.00)和镇痛药(RR:0.93,95%CI 0.90–0.96)处方低于预期
  • 抗抑郁药(RR:0.93,95%CI 0.89–0.98)和外用抗真菌制剂(RR:0.92,95%CI 0.86–0.99)处方低于预期
  • 降压药处方在启动后仍继续上升,但增速慢于预期(RR:0.92,95%CI 0.89–0.95)
  • 降糖药处方下降(RR:0.87,95%CI 0.82–0.92),主要是非胰岛素类药物,但阴性对照队列中也观察到类似下降

关键数值与推荐

  • 抗哮喘药 RR:0.82,95%CI 0.79–0.86
  • 外用糖皮质激素 RR:0.91,95%CI 0.87–0.96;抗银屑病药 RR:0.91,95%CI 0.83–1.00
  • 镇痛药 RR:0.93,95%CI 0.90–0.96;抗抑郁药 RR:0.93,95%CI 0.89–0.98
  • 外用抗真菌制剂 RR:0.92,95%CI 0.86–0.99;降压药 RR:0.92,95%CI 0.89–0.95
  • 降糖药 RR:0.87,95%CI 0.82–0.92;抗焦虑药 RR:1.16,95%CI 1.08–1.24

临床怎么用

  • 启动司美格鲁肽用于体重管理后,可关注哮喘、皮肤疾病、疼痛和情绪相关合并用药处方的变化
  • 治疗期间应监测抗焦虑药使用增加的可能,并注意评估焦虑相关症状
  • 降糖药处方减少需结合血糖控制情况判断,同时考虑非胰岛素类降糖药的调整

局限性

  • 研究使用处方数据,不反映实际服药依从性和临床适应证变化
  • 降糖药减少在阴性对照队列中也有类似表现,提示该变化可能不特异
  • 抗焦虑药增加的原因无法从处方数据中确定,可能存在混杂因素

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To evaluate the impact of semaglutide initiation for weight management on the use of concomitant medications commonly prescribed for obesity-related comorbidities. Materials and Methods We conducted a nationwide interrupted time series study using data from Danish registers, including adults initiating semaglutide for weight management between 12/2022 and 12/2024. Monthly prescriptions for 10 medication classes were analysed in the 24 months before and 12 months after initiation. Effects at 12 months were expressed as rate ratios (RRs) comparing observed values with expected values based on pre-initiation trends. Results Among 189 392 semaglutide initiators (68% women; median age 50 years), prescription volumes at 12 months declined and were lower than projected from pre-initiation trends for antiasthmatics (RR: 0.82, 95% confidence interval 0.79–0.86), topical corticosteroids (0.91, 0.87–0.96), antipsoriatics (0.91, 0.83–1.00), analgesics (0.93, 0.90–0.96), antidepressants (0.93, 0.89–0.98) and topical antifungal formulations (0.92, 0.86–0.99). Antihypertensive prescriptions continued to rise after semaglutide initiation, but more slowly than projected (0.92, 0.89–0.95). Glucose-lowering medications declined (0.87, 0.82–0.92), mainly non-insulin agents, but a similar reduction was observed in the negative control cohort. Anxiolytic use increased (1.16, 1.08–1.24) and remained elevated at 2 years. Changes in lipid-modifying agents and medications for gastric acid disorders were small or transient. Conclusions Semaglutide initiation for weight management was associated with reduced use of several concomitant medications for obesity-related comorbidities, while anxiolytic use increased. Changes in other therapeutic classes were limited. These findings suggest that semaglutide treatment may influence overall medication use and support continued monitoring of prescribing patterns during therapy.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。